Azithromycin belongs to a class of antibiotics called Macrolides. It works by inhibiting bacterial protein synthesis, quorum-sensing and reducing the formation of biofilm.
Bacterial protein is the main cause of various infections. Quorum sensing is a process of cell–cell communication that allows bacteria to share information amongst themselves and adjust their gene expression accordingly. Biofilm is the film formed by bacterial secretions that holds the bacteria together. Bacterial biofilm is also infectious in nature and can results in various infections.
Azithromycin accumulates effectively in cells of immune system and is delivered in to sites of infection. Azee is prescribed for any of the following indications:
Skin and soft tissue infections
Respiratory tract infections
Uncomplicated genital infections due to Chlamydia trachomatis
Non-gonococcal cervicitis/urethritis due to Chlamydia trachomatis
Active immunisation against typhoid fever caused by Salmonella typhi
Azee is a product from Cipla limited which is an Indian multinational pharmaceutical and biotechnology company. It is primarily into development of medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression and other medical conditions. The company’s goal is ensuring that no patient shall be denied access to high quality and affordable medicines and support with the vision to make India self-sufficient in health care.
This antibiotic is used for a variety of severe bacterial infections.
Pnemonia is an infection that inflames the air sacs in one or both lungs. The air sacs may fill with fluid or pus (purulent material), causing cough with phlegm or pus, fever, chills, and difficulty breathing
Hospital-acquired pneumonia – Some people catch pneumonia during a hospital stay for another illness. Hospital-acquired pneumonia can be serious because the bacteria causing it may be more resistant to antibiotics and because the people who get it are already sick. People who are on breathing machines (ventilators), often used in intensive care units, are at higher risk of this type of pneumonia.
Septicemia is a life-threatening complication of an infection. Sepsis occurs when chemicals released in the bloodstream to fight an infection trigger inflammation throughout the body. This can cause a cascade of changes that damage multiple organ systems, leading them to fail, sometimes even resulting in death.
As directed by your Physician
As directed by your Physician
Adverse Reactions/ Side Effects
Significant: Myasthenia gravis. Ear and labyrinth disorders: Deafness. Eye disorders: Pruritus, burning, stinging of the eye or ocular discomfort, sticky eye sensation, foreign body sensation (ophthalmic). Gastrointestinal disorders: Diarrhoea, vomiting, abdominal pain, nausea, flatulence, dyspepsia, dysgeusia. General disorders and administration site conditions: Injection site pain, fatigue. Investigations: Decreased lymphocyte count and blood bicarbonate; increased eosinophil count, basophils, monocytes and neutrophils. Metabolism and nutrition disorders: Anorexia. Musculoskeletal and connective tissue disorders: Arthralgia. Nervous system disorders: Headache, dizziness, paraesthesia. Skin and subcutaneous tissue disorders: Pruritus, rash.
Potentially Fatal: Rarely, serious hypersensitivity reactions (e.g. anaphylaxis, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalised exanthematous pustulosis drug reaction with eosinophilia and systemic symptoms), fulminant hepatitis leading to liver failure, prolonged cardiac repolarisation and QT interval, cardiac arrhythmia, torsades de pointes, Clostridium difficile associated diarrhea (CDAD).
Warnings and Precautions
Patients with myasthenia gravis, electrolyte disturbance particularly hypokalaemia and hypomagnesaemia; bradycardia, cardiac arrhythmia, severe cardiac insufficiency, congenital or documented QT prolongation, history of torsades de pointes. Severe renal (GFR <10 mL/min) and hepatic impairment. Children. Pregnancy and lactation. Azithromycin should not be given long-term to prevent bronchiolitis obliterans syndrome in patients with cancers of the blood or lymph nodes who undergo a hematopoietic stem cell transplant. Patient Counselling Ophthalmic: Avoid using contact lenses during treatment. This drug may cause blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor liver function values and blood count with differential. Perform culture and susceptibility testing before initiating therapy.
Hypersensitivity to macrolide antibiotics. History of hepatic dysfunction/cholestatic jaundice following previous antibiotic use.
Increased risk of prolonged QT interval with class IA (e.g. quinidine, procainamide) and class III (e.g. dofetilide, amiodarone, sotalol) antiarrhythmics; pimozide cisapride and terfenadine. Increased serum concentrations of digoxin, colchicine, and ciclosporin. May potentiate the effects of oral anticoagulants (e.g. warfarin).
Symptoms: Diarrhoea, reversible hearing loss, severe nausea and vomiting. Management: Initiate symptomatic and supportive measures as necessary.
Intravenous: Injection: Store below 30°C. Ophthalmic: Eye drop (1.5%): Store below 25°C. Protect from light. Eye drop (1%): Store between 2-8°C. Oral: Tab/Immediate release suspension: Store below 30°C. Cap/Eye drop: Store below 25°C. Protect from light.
Mechanism of Action
Azithromycin is a macrolide antibiotic under the azalide group. It inhibits RNA-dependent protein synthesis by binding to the 50s ribosomal subunit, preventing the translocation of peptide chains.